HLA class II genes are highly associated with IDDM, a trait linked to the polymorphic sequences present in specific """"""""risk-allele"""""""". Remarkably, this polymorphism extends through the upstream gene sequences, including the promoter and related transcriptional regulatory elements. Within this polymorphic regulatory region, nucleotide variation in and around the """"""""x- box"""""""" element corresponds to differences in locus-specific and allele- specific transcription. A reasonable model to account for these non- coordinate aspects of HLA class II expression is that conserved protein interaction with consensus elements in the promoter region are a prerequisite for gene expression, capable of interaction with a smaller subset of factors specific for locus and allelic sequence variation concentrated in the x-box region, which is accomplished by additions and perturbations to the more general class II regulatory complex. We propose to characterize these locus-and allele-specific interactions unique to the HLA-DQB1 genes which are implicated in susceptibility to IDDM. We will identify DNA binding proteins which recognize polymorphic sites associated with the HLA-DQB1 promoter, and study their mechanisms of action using specific target site inhibitors of the transcription complex. We will analyze variation in DQB1 endogenous gene expression among different cell types in patients who differ for disease phenotypes, specifically in at- risk """"""""non-progressors"""""""", late-onset IDDM, and auto-antibody-positive NIDDM, in conjunction with projects 3 and 4. We will analyze in depth the role of YY1, the first transcription factor which we have identified modulating DQB1 expression which binds DQ promoters in an allele-specific fashion. In conjunction with project 2, we will assess the impact of altered DQ expression on antigen presentation of defined GAD-Ab complexes. We will analyze the interactions between viral proteins and the YY1 transactivation domain to determine in environmental stimuli such as viruses modulate DQ expression and function. Understanding the non- coordinate aspects of HLA class II expression represents fundamental new information relevant to cellular development and differentiation, as well as for mechanisms contributing to IDDM and other HLA-associated diseases.

Project Start
2001-12-01
Project End
2003-11-30
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
$180,000
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Zhao, Lue Ping; Bolouri, Hamid; Zhao, Michael et al. (2016) An Object-Oriented Regression for Building Disease Predictive Models with Multiallelic HLA Genes. Genet Epidemiol 40:315-32
Hao, Wei; Greenbaum, Carla J; Krischer, Jeffrey P et al. (2015) The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance. Diabetes Care 38:891-6
Brooks-Worrell, Barbara M; Boyko, Edward J; Palmer, Jerry P (2014) Impact of islet autoimmunity on the progressive ?-cell functional decline in type 2 diabetes. Diabetes Care 37:3286-93
Eringsmark Regnéll, S; Lernmark, A (2013) The environment and the origins of islet autoimmunity and Type 1 diabetes. Diabet Med 30:155-60
Brooks-Worrell, B M; Palmer, J P (2013) Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 171:164-70
Skoglund, Camilla; Chéramy, Mikael; Casas, Rosaura et al. (2012) GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes. Pediatr Diabetes 13:244-50
Nepom, Gerald T (2012) MHC class II tetramers. J Immunol 188:2477-82
Oak, S; Radtke, J; Torn, C et al. (2011) Immunoglobulin subclass profiles of anti-idiotypic antibodies to GAD65Ab differ between type 1 diabetes patients and healthy individuals. Scand J Immunol 74:363-7
Brooks-Worrell, Barbara M; Reichow, Jessica L; Goel, Amit et al. (2011) Identification of autoantibody-negative autoimmune type 2 diabetic patients. Diabetes Care 34:168-73
Vaziri-Sani, Fariba; Oak, Shilpa; Radtke, Jared et al. (2010) ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 43:598-606

Showing the most recent 10 out of 86 publications